Patents by Inventor John M. Brackett

John M. Brackett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8592600
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: November 26, 2013
    Assignee: Il Yang Pharmaceutical Company, Ltd.
    Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent, Jinyu Shen
  • Patent number: 8592599
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: November 26, 2013
    Assignee: Il Yang Pharmaceutical Company, Ltd.
    Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent, Jinyu Shen
  • Patent number: 7999110
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2 -pyridinyl)-methyl]sulfinyl]-5-(1 H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: August 16, 2011
    Assignee: IL Yang Pharmaceutical Company, Ltd.
    Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent, Jinyu Shen
  • Patent number: 7989632
    Abstract: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: August 2, 2011
    Assignee: Il Yang Pharmaceutical Company, Ltd.
    Inventors: John M. Brackett, David T. Jonaitis, Wei Lai, Jih Hua Liu, Stephan D. Parent
  • Publication number: 20110082174
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: November 4, 2010
    Publication date: April 7, 2011
    Applicant: IL YANG PHARMACEUTICAL COMPANY, LTD.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
  • Publication number: 20110046184
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: November 4, 2010
    Publication date: February 24, 2011
    Applicant: IL YANG PHARMACEUTICAL COMPANY, LTD.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
  • Publication number: 20080200516
    Abstract: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT, Jinyu SHEN
  • Publication number: 20080200517
    Abstract: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
  • Publication number: 20080200515
    Abstract: The invention relates to solid state forms of enantiopure ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfnyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a solid form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders such as those discussed above.
    Type: Application
    Filed: December 28, 2007
    Publication date: August 21, 2008
    Applicant: TAP PHARMACEUTICAL PRODUCTS INC.
    Inventors: John M. BRACKETT, David T. JONAITIS, Wei LAI, Jih Hua LIU, Stephan D. PARENT
  • Patent number: 5643721
    Abstract: The present invention provides an immobilization medium which can immobilize bioreagents to support materials and which dries to a water resistant layer or film. The immobilization medium comprises (i) a liquid or fluid binding reagent and (ii) complexes of a bioreagent immobilized to a solid phase which are evenly dispersed within the binding reagent. The suspension can further include supplemental ingredients evenly dispersed throughout the medium which can provide the medium with electrochemical properties, enhance the stability of the immobilized bioreagent and/or improve the medium's capability of drying to a substantially water resistant or insoluble layer. The immobilization medium provided by the instant invention is in the form of a homogeneous liquid suspension.
    Type: Grant
    Filed: February 9, 1994
    Date of Patent: July 1, 1997
    Assignee: Abbott Laboratories
    Inventors: Thomas G. Spring, John M. Brackett, Sheila A. Vogdes, Steven G. Schultz
  • Patent number: 5597702
    Abstract: Detection of lead present in a sample, comprising the steps of: (a) adding a lead recovery agent to an assay solution containing lead from the sample; (b) adding to the assay solution a disulfide enzyme which is inhibited in the presence of lead; and (c) correlating the activity of the disulfide enzyme to the amount of lead in the sample. The lead recovery agent enhances the sensitivity and accuracy of the assay such that the assay can be readily automated for detection of lead in whole blood using commercially available automation systems.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: January 28, 1997
    Assignee: Abbott Laboratories
    Inventors: Martin Wong, David M. Finley, John M. Ramp, Gary L. Boltinghouse, Jr., Mark R. Shaffar, Stephen D. Stroupe, John M. Brackett
  • Patent number: 5552297
    Abstract: A method and kit for simplifying and improving the sensitivity and accuracy of a lead assay for a sample solution suspected of containing lead determines the extent of a reaction between a substrate and a disulfide enzyme in the presence of an activating reagent which contains a water-soluble tertiary phosphine reagent so as to increase the activity of the disulfide enzyme for reaction with the substrate. For a colorimetric determination of the enzyme activity a chromophore is formed upon reaction with a selected component of the sample solution in the presence of a colorimetric enhancing reagent. The colorimetric enhancing reagent contains a metal ion such as cupric ion or ferric ion which is soluble in the sample solution. The extent of the chromophore formation is then photometrically determined.
    Type: Grant
    Filed: April 11, 1995
    Date of Patent: September 3, 1996
    Assignee: Abbott Laboratories
    Inventors: Martin Wong, John M. Ramp, John M. Brackett